

LET OUR ACTIONS COUNT



NATIONAL AIDS SPENDING ASSESSMENT+
HIV and TB SPENDING IN SOUTH AFRICA: 2021/22 – 2023/24



South Africa National AIDS & TB Spending Assessment (NASA+) 2021/22-2023/24

Final results
July 2025



THE SOUTH AFRICAN NATIONAL AIDS COUNCIL
THE SOUTH AFRICAN AIDS COUNCIL [SANAC] BRINGS TOGETHER GOVERNMENT, CIVIL SOCIETY AND THE PRIVATE SECTOR TO CREATE A COLLECTIVE RESPONSE TO HIV, TB AND STIS IN SOUTH AFRICA. THE COUNCIL IS CHAIRED BY THE DEPUTY PRESIDENT OF SOUTH AFRICA.

National AIDS Spending Assessments

- UNAIDS continues to promote and support NASA – latest version 2024
 - Framework, guidelines and software have been updated
- **NASA data can be used for:**
- Tracking spending (from all sectors) according to the country's priorities outlined in the National AIDS Strategic Plan (NSP) – are partners aligning
- Global Fund request for funding – the funding landscape
- Sustainability planning – understanding the current donor dependency
- GAM reporting to use AIDS Spending Categories (ASC) - (indicator 8.1)
- Flexible to include new services, e.g. PrEP, KPs (prisoners, transgender), TB
- AIDS Spending Categories (ASCs) can track expenditure according to the Resource Needs (RN) Categories = services with “proven impact” = **allocative efficiency**
- Allows for the measure of the funding gaps – for financing and resource mobilization
- Analysis of production factors = cost drivers giving some insight into **technical efficiencies**
- Leads to routine collection of financial data – should be part of the SANAC's routine M&E
- Allows for time-trend analysis, with comparable categories over time and globally

NASA attempts to answer the following questions

- **Total** (in-country expenditures) compared to NSP cost estimates → **Adequacy? Allocative efficiency**
- **Financing**: Who pays and who purchase? Time trends?
 - *Financial Entities (Sources)* → **dependency (sustainability?)**
 - *Financial Agents* → **strategic purchasing?**
 - *Revenue* → **What mechanisms are used to finance the schemes? Pooling / insurances / direct transfers?**
 - *Financing scheme* → **What modalities are used through which beneficiaries access services?**
- **Provision**
 - What cost components? (*Production Factors*) → **technical efficiency?**
 - Who provides the services? (*Providers*) → **response actors/ mapping**
 - Service Delivery Modality → **What are the service delivery models**
- **Utilization**
 - Who benefits? (*Beneficiary Populations*) → **focus on KPs / equity? Cost per output?**
 - What was provided? (*Aids Spending Categories*) → **allocative efficiency? Value for Money?**

Scope of South African NASA+

- NASA covers FYs: 2021/22, 2022/23 and 2023/24
- NASA includes **HIV and TB (all)** expenditures.
- NASA does not usually include all TB expenditure, only the TB/HIV interventions for PLHIV. Hence this is called a *NASA-plus*.
- **Included Sources of funding:** public (ALL depts), external (dev.partners), private businesses (No response yet) & medical insurances (*excluding individuals & households*)
- **Providers:** public, parastatals, NGOs, universities, businesses, external

NASA Principles

1. DATA triangulation (cross check data from different sources (Source, Agent & Provider).
2. Only capture complete transactions
3. Only Capture actual expenditure, not budgets or commitment
4. NASA must be exhaustive covering entities, services and expenditures
5. The NASA categories and record/report must be consistent over time and comparable across countries
6. NASA using the 'matching' principle (accrual vs cash accounting) – as far as possible

Matching Method: Accounting method that records revenues and expenses when they are incurred, regardless of when cash is exchanged. Income and expenses are recorded as they occur, regardless of whether or not cash has actually changed hands.

(Matching accounting is opposed to cash basis accounting. Cash Method: Income is recorded when it's received, and expenses are reported when they're actually paid, whenever cash has actually changed hands.)

NASA Methodology

- The CEGAA team applied the NASA methodology according to UNAIDS Guidance:
- Data collection electronically, and through interviews where necessary & expenditure record verification.
- PEPFAR data came from the ER reports (ER21, ER22, ER23, ER24) – EARTH team assisted with crosswalking but provincial split was not done yet due to the stop-work orders from US government.
- All public expenditure obtained from the national and provincial BAS records (Vulindlela files)
- BASLY – software developed by HE2RO/FINCAP/NDOH/SANAC to extract and label HIV and TB expenditure from DOH BAS records – expanded to other departments
- Data triangulation to ensure correct actual expenditure.
 - Verification of expenditure data with key stakeholders.
- Double counting avoided through triangulation & creating transactions.
- Data cleaned and captured in Excel.
- Exported to NASA RTT where aggregated and matrices produced.
- All analysis & graphs generated in Excel. Draft results to be discussed with stakeholders & reviewed by UNAIDS.

Overview of data captured

- 98% of public funding was captured (national & provincial departments)
- 95% of international funding was captured (through PEPFAR and GF databases) as well as some others UN agencies (& those reported by NGOs)
- 90% (estimated) of NGOs, research agencies other service providers were captured through the databases of NDOH, DSD, PEPFAR and GF
- 98% of private medical insurances' expenditure were captured – collated by the Council of Medical Schemes
- Research agencies & universities – difficult to quantify the magnitude of entire funding for these, but it is estimated about half of the key ones was reported by PEPFAR

Limitations

- Limited Private Sector Data**

Very low response rate from private-for-profit entities; private expenditure largely excluded (except CMS data).

- Partial Data Disaggregation**

About 7% of 2023/24 expenditure could not be broken down by production factors—still indicates good data quality.

- Fiscal Year Misalignment**

Differences in fiscal calendars (e.g., PEPFAR) led to minor misalignments—considered negligible over time.

- Indirect Costs Excluded**

No estimates for costs embedded in general health budgets (e.g., nurse time).

Hidden expenditures intentionally excluded to maintain data credibility; minor impact on overall trends.

- No Out-of-Pocket (OOP) Costs**

Household-level spending not included; assumed to be low due to free ART, but may burden poor households.

- Limited Provincial Disaggregation**


Sub-national analysis limited to public and medical scheme data; most donor funding not broken down by province.

NASA FINDINGS:

- i. Total picture – all HIV sources (financing entities), revenues, schemes, financing agents & purchasers and providers of services:
Financing Flows**

TOTAL EXPENDITURE ON HIV AND TB IN SOUTH AFRICA


(2021/22 - 2023/24, ZAR billions)



HIV and TB are presented together here, but following slides separate HIV from TB

TIME TRENDS HIV EXPENDITURE IN SOUTH AFRICA


(2013/14-2023/23, ZAR billions, %)



Over this period, the HIV incidence rate (new infections per 1,000 population) steadily declined from above 5.5 in 2013/14 to below 3.5 in 2023/24. This inverse relationship suggests that sustained and increased investment in the HIV response has contributed significantly to reducing new HIV infections, demonstrating the positive impact of continued financial commitment on epidemic control

HIV only: FINANCING ENTITIES IN SOUTH AFRICA

(2021/22-2023/24, ZAR, USD, %)




HIV Funding Entities (ZAR)	2021/22	2022/23	2023/24	% 2021/22	% 2022/23	% 2023/24
Government of South Africa	29,068,994,920	29,974,849,507	29,074,644,515	74%	76%	76%
PEPFAR	8,216,515,262	7,470,234,250	7,162,583,331	21%	19%	19%
Global Fund	926,399,287	681,020,602	933,509,576	2%	2%	2%
Other bilateral funding entities	6,495,978	12,406,659	18,087,000	0.0%	0.0%	0.0%
Other multilateral funding entities	77,658,964	96,374,350	58,450,972	0.2%	0.2%	0.2%
INGOs and Foundations	3,005,662	504,057	486,476	0.0%	0.0%	0.0%
Medical insurances	889,346,480	1,043,107,979	1,026,902,624	2.3%	2.7%	2.7%
Private sector / domestic corporations	432,706	432,706	523,694	0.0%	0.0%	0.0%
Total HIV (ZAR)	39,188,849,259	39,278,930,110	38,275,188,187	100%	100%	100%

HIV Funding Entities (USD)	2021/22	2022/23	2023/24	% 2021/22	% 2022/23	% 2023/24
Government of South Africa	1,966,779,088	1,829,966,392	1,575,007,829	74%	76%	76%
PEPFAR	555,921,195	456,058,257	388,005,598	21%	19%	19%
Global Fund	62,679,248	41,576,349	50,569,316	2%	2%	2%
Other bilateral funding entities	439,511	757,427	979,794	0.0%	0.0%	0.0%
Other multilateral funding entities	5,254,328	5,883,660	3,166,358	0.2%	0.2%	0.2%
INGOs and Foundations	203,360	30,773	26,353	0%	0%	0%
Other international entities	31,392	-	-	0.0%	0.0%	0.0%
Medical insurances	60,172,292	63,681,806	55,628,528	2%	3%	3%
Private sector / domestic corporations	29,276	26,417	28,369	0.0%	0.0%	0.0%
Total HIV (USD)	2,651,509,691	2,397,981,081	2,073,412,144	100%	100%	100%

FINANCING REVENUES FOR HIV IN SA

(2021/22 - 2023/24, ZAR billions)




FINANCING ENTITIES AND THEIR SCHEMES FOR HIV

(2021/22 - 2023/24, ZAR billions)

HIV Financing Entities and their Financing Schemes (ZAR)	2021	2022	2023
FE.01 Public Entities	29,068,994,920	29,974,849,507	29,074,644,515
SCH.01 Government schemes and compulsory contributory health care schemes	29,068,994,920	29,974,849,507	29,074,644,515
FE.02 Domestic Private Entities	889,779,186	1,043,540,685	1,027,426,317
SCH.01 Government schemes and compulsory contributory health care schemes			90,988
SCH.02 Voluntary payment schemes	889,779,186	1,043,540,685	1,027,335,330
SCH.02.01 Voluntary insurance schemes	889,346,480	1,043,107,979	1,026,902,624
SCH.02.01.98 Voluntary insurance schemes not directly funded by government	889,346,480	1,043,107,979	1,026,902,624
SCH.02.02 Not-for-profit schemes (including resident foreign agencies schemes)	432,706	432,706	432,706
SCH.02.02.01 Not-for-profit organisation schemes	432,706	432,706	432,706
FE.03 International Entities	9,230,075,153	8,260,539,917	8,173,117,355
SCH.01 Government schemes and compulsory contributory health care schemes	495,942,142	562,720,179	721,917,105
SCH.02 Voluntary payment schemes	8,681,655,601	7,667,786,746	7,417,201,157
SCH.02.02 Not-for-profit schemes (including resident foreign agencies schemes)	8,395,735,215	7,558,133,899	7,285,192,128
SCH.02.02.01 Not-for-profit organisation schemes	8,274,020,386	7,423,607,561	7,191,953,250
SCH.02.02.02 Resident foreign agencies schemes	121,714,830	134,526,338	93,238,878
SCH.02.03 For-profit organizations schemes	285,920,386	109,652,847	132,009,029
SCH.04 External schemes (non-resident)	52,477,410	30,032,992	33,999,093
SCH.04.02 Voluntary schemes (non-resident)	52,477,410	30,032,992	33,999,093
Grand Total	39,188,849,259	39,278,930,110	38,275,188,187

FINANCING AGENTS & PURCHASERS FOR HIV

(2021/22 - 2023/24, ZAR billions)



HIV Financing Agents and Purchasers (ZAR)	2021/22	2022/23	2023/24	% 2021/22	% 2022/2	% 2023/2
Government entities	29,437,877,745	30,314,629,860	29,570,371,735	75%	77%	77%
Private insurance enterprises	889,346,480	1,043,107,979	1,026,902,624	2%	3%	3%
Domestic Not-for-profit organizations	565,785,133	357,946,334	457,994,693	1%	1%	1%
Multilateral agencies	79,324,639	93,011,687	57,335,803	0.00	0.00	0.00
Country offices of bilateral agencies	8,216,515,262	7,470,234,250	7,162,583,331	21%	19%	19%
Total	39,188,849,259	39,278,930,110	38,275,188,187	100%	100%	100%


FINANCING AGENTS & PURCHASERS WITH THEIR FINANCING ENTITIES

(2021/22 - 2023/24, ZAR billions)

Financing Agents with their Financing Entities (ZAR)	2021	2022	2023
FE.01 Public Entities	29,068,994,920	29,974,849,507	29,074,644,515
FAP.01.01 Territorial governments	29,068,994,920	29,974,849,507	29,074,644,515
FE.02 Domestic Private Entities	889,779,186	1,043,540,685	1,027,426,317
FAP.01.01 Territorial governments			90,988
FAP.02.03 Domestic Private insurance For-profit orga	889,346,480	1,043,107,979	1,026,902,624
FAP.02.05 Domestic Not-for-profit organizations	432,706	432,706	432,706
FE.03 International Entities	9,230,075,153	8,260,539,917	8,173,117,355
FAP.01.01 Territorial governments	368,882,825	339,780,353	495,636,233
FAP.02.05 Domestic Not-for-profit organizations	565,352,427	357,513,628	457,561,987
FAP.03.02 Multilateral agencies managing external re	79,324,639	93,011,687	57,335,803
FAP.03.99 Other international financing agents n.e.c.	8,216,515,262	7,470,234,250	7,162,583,331
Grand Total	39,188,849,259	39,278,930,110	38,275,188,187

SERVICE PROVIDERS FOR HIV SERVICES in SA

(2021/22 - 2023/24, ZAR billions)



HIV Service Providers (ZAR)	2021/22	2022/23	2023/24	% 2021/22	% 2022/23	% 2023/24
Public service providers	29,346,529,147	30,222,390,818	29,494,395,081	75%	77%	77%
Univ. & Research orgs	49,121,463	142,148,670	130,062,407	0%	0%	0%
NGOs (local)	8,080,584,899	7,223,507,358	6,893,308,489	21%	18%	18%
For-profit providers	1,153,481,589	1,131,151,315	1,127,058,111	3%	3%	3%
Multilateral agencies	109,661,380	87,599,776	78,797,538	0.3%	0.2%	0.2%
INGOs & Foundations	375,208,095	420,489,670	485,713,927	1.0%	1.1%	1.3%
International research centers and other for-profit	21,785,277	21,609,512	31,853,542	0.1%	0.1%	0.1%
International agencies in-country	52,477,410	30,032,992	33,999,093	0.1%	0.1%	0.1%
Total	39,188,849,259	39,278,930,110	38,275,188,187	100%	100%	100%

SERVICE PROVIDERS FOR HIV SERVICES in SA


(2021/22 - 2023/24, ZAR billions)

Providers of HIV Services per Sector (ZAR)	2021/22	2022/23	2023/24	% 2023/24
PS.01.01 Governmental organizations	29,346,529,147	30,222,390,818	29,494,395,081	77%
Clinics/Hospitals	22,001,388,971	23,808,249,007	23,245,584,737	61%
Pharmacies	-	8,190,000	11,999,000	0%
Schools and Universities (public)	298,616,491	240,327,690	250,955,723	1%
Other public departments (DOH, DSD, DBE, SANAC etc.)	7,046,523,685	6,165,624,121	5,985,855,621	16%
PS.01.02 Parastatal organizations	49,121,463	142,148,670	130,062,407	0%
Labs	14,365,318	8,305,954	13,337,040	0%
Research institutions	34,756,145	133,842,716	116,725,367	0%
PS.02.01 Non-profit providers	8,080,584,899	7,223,507,358	6,893,308,489	18%
NGOs (non-faith-based)	8,039,658,360	7,198,350,315	6,883,150,383	18%
NGOs (faith-based)	40,926,539	25,157,042	10,158,106	0%
PS.02.02 Profit-making private sector providers	1,153,481,589	1,131,151,315	1,127,058,111	3%
Hospitals (profit-making private)	188,777,361	204,661,836	240,153,962	1%
Clinics (profit-making private)	866,818,343	838,450,746	786,748,662	2%
Research institutions (profit-making private)	4,434,000	982,800	-	0%
Consultancy firms (profit-making private)	84,590,640	87,055,933	83,785,565	0%
Profit-making providers not disagg.	8,861,246	-	16,369,922	0%
PS.03 International providers	559,132,161	559,731,950	630,364,099	2%
Multilateral agencies	109,661,380	87,599,776	78,797,538	0%
International NGOs and foundations	375,208,095	420,489,670	485,713,927	1%
International research centers and other for-profit	21,785,277	21,609,512	31,853,542	0%
Other International providers – in country offices n.e.c.	52,477,410	30,032,992	33,999,093	0%
Grand Total	39,188,849,259	39,278,930,110	38,275,188,187	100%

HIV programmes & interventions (ASC)

TOTAL HIV SPENDING – by programme area

(2021/22 - 2023/24, ZAR billions)




Total HIV spending per programme area (ZAR)	2021/22	2022/23	2023/24	% 2021/22	% 2022/23	% 2023/24
Prevention	3,591,219,091	3,519,238,139	4,203,121,076	9%	9%	11%
HIV testing and counselling (HTC)	1,257,150,416	1,375,165,609	1,404,158,397	3%	4%	4%
HIV Care and Treatment	28,600,812,542	28,865,834,421	27,465,903,193	73%	73%	72%
Social protection and economic support	1,919,040,616	1,894,377,838	1,667,513,466	5%	5%	4%
Social enablers	7,100,807	8,323,029	11,536,658	0.0%	0.0%	0.0%
Programme enablers and systems strengthening	3,319,390,648	3,167,488,549	3,277,928,723	8%	8%	9%
Development synergies	494,135,138	447,739,805	231,328,909	1%	1%	1%
HIV-related research	-	762,720	13,697,765	0%	0%	0%
Total HIV spending (ZAR)	39,188,849,259	39,278,930,110	38,275,188,187	100%	100%	100%

TOTAL HIV SPENDING – programme area by FE


(2021/22 - 2023/24, ZAR billions)

HIV Programme areas by FE (ZAR) - 2023/24	Public Entities	Domestic Private Entities	International Entities	Total per Programme Area	% Public	% Private	% Int. Entities
Prevention	2,234,323,376	-	1,768,802,410	4,003,125,786	56%	0%	44%
HIV testing and counselling (HTC)	1,288,310,580	432,706	115,415,111	1,404,158,397	92%	0%	8%
HIV Care and Treatment	22,585,805,385	1,026,902,624	4,053,190,475	27,665,898,483	82%	4%	15%
Social protection and economic support	1,323,018,289	-	344,495,176	1,667,513,466	79%	0%	21%
Social enablers	-	-	11,536,658	11,536,658	0%	0%	100%
Programme enablers and systems strengthening	1,453,720,375	90,988	1,824,117,360	3,277,928,723	44%	0%	56%
Development synergies	189,466,509	-	41,862,399	231,328,909	82%	0%	18%
HIV related research	-	-	13,697,765	13,697,765	0%	0%	100%
Total Public HIV (ZAR)	29,074,644,515	1,027,426,317	8,173,117,355	38,275,188,187	435%	4%	361%



DEEPER DIVE into SPENDING on HIV CARE & TREATMENT



(2021/22 - 2023/24, ZAR billions)



Spending on Care & Treatment activities (ZAR)	2021/22	2022/23	2023/24	% 2021/22	% 2022/23	% 2023/24
ART	12,664,177,502	10,991,388,198	10,933,326,085	44%	38%	40%
Community outreach, HBC, adherence & support	3,252,550,426	2,509,521,324	1,832,056,962	11%	9%	7%
Specific ART-related laboratory monitoring	4,662,707,011	6,114,717,806	5,586,254,179	16%	21%	20%
Co-infections and opportunistic infections	-	4,557,525	5,559,013	0%	0%	0%
Palliative care (and step-down care)	5,106,211	9,163,070	15,545,463	0%	0%	0%
Care and treatment services not disagg.	8,016,271,391	9,236,486,498	9,093,161,491	28%	32%	33%
Grand Total	28,600,812,542	28,865,834,421	27,465,903,193	100%	100%	100%

HIV CARE & TREATMENT BY FINANCING ENTITIES



(2023/24, ZAR bn)



HIV Care and Treatment activities (2023/24)	Public entities	Medical insurances	International entities
ART	9,417,694,495	1,026,902,624	488,728,967
COS, adherence and support	1,832,056,962	-	-
ART lab monitoring	5,574,737,134	-	11,517,045
Co-infections and opportunistic infections	-	-	5,559,013
Care and treatment services not disagg.	5,545,776,041	-	3,547,385,450
Total Care and Treatment (ZAR)	22,385,810,095	1,026,902,624	4,053,190,475

DEEPER DIVE into HIV PREVENTION SPENDING

(2021/22 - 2023/24, ZAR billions)




HIV PREVENTION SPENDING by INTERVENTION

(2021/22 - 2023/24, ZAR billions)

HIV Prevention interventions (ZAR)	2021/22	2022/23	2023/24	% 2021/22	% 2022/23	% 2023/24
Five Pillars of Prevention	2,484,189,072	2,410,607,107	2,691,714,790	69%	68%	64%
Prevention for AGYW	459,165,232	326,856,172	304,745,482	13%	9%	7%
Services for key populations	425,604,941	321,086,330	335,985,288	12%	9%	8%
Condoms for gen.population	462,492,688	388,369,215	729,101,929	13%	11%	17%
VMMC	890,713,475	1,049,885,904	989,078,061	25%	30%	24%
Pre-Exposure Prophylaxis (PrEP)	246,212,736	324,409,486	332,804,031	7%	9%	8%
Other Prevention activities	1,107,030,020	1,108,631,032	1,511,406,286	31%	32%	36%
PMTCT	310,064,748	321,937,930	357,317,025	9%	9%	9%
Activities for vulnerable and accessible populations	-	16,332,111	43,287,464	0%	0%	1%
Prevention for children and youth (excl. for AGYW)	275,687,375	237,796,406	250,196,988	8%	7%	6%
SBCC	86,782,150	140,448,766	164,233,403	2%	4%	4%
Community mobilization	47,597,576	84,963,486	115,697,807	1%	2%	3%
Wellness programmes in the workplace	2,548,062	852,475	204,170	0%	0%	0%
Post-exposure prophylaxis (PEP)	13,529,874	15,920,005	20,453,171	0%	0%	0%
Other Prevention activities not disagg	31,937,710	25,454,615	31,766,262	1%	1%	1%
Other prevention activities n.e.c	-	-	314,524,508	0%	0%	7%
Prevention activities not disaggregated	115,228,206	72,576,160	13,730,197	3%	2%	0%
HPV vaccination	223,654,318	192,349,077	199,995,290	6%	5%	5%
Total Prevention spending (ZAR)	3,591,219,091	3,519,238,139	4,203,121,076	100%	100%	100%



HIV PREVENTION SPENDING by FINANCING ENTITY

(2021/22 - 2023/24, ZAR billions)





HTC ACTIVITIES & FINANCING ENTITY

(2021/22 - 2023/24, ZAR millions)



SOCIAL PROTECTION & ECONOMIC SUPPORT ACTIVITIES & FINANCING ENTITY



(2021/22 - 2023/24, ZAR billions)



Social Protection and Economic Support	2021/22	2022/23	2023/24	% 2021/22	% 2022/23	% 2023/24
For OVC	312.792.713	310.997.411	324.053.818	16%	16%	19%
OVC basic needs	146.543.045	177.405.391	207.910.476	8%	9%	12%
OVC social services	-	18.198.213	13.156.579	0%	1%	1%
OVC services not disagg.	166.249.667	115.393.808	102.986.762	9%	6%	6%
For non-OVC	1.606.247.903	1.583.380.427	1.343.459.648	84%	84%	81%
Monetary or in-kind benefits (non-OVC)	-	-	4.207.982	0%	0%	0%
Social services (non-OVC)	-	-	4.207.982	0%	0%	0%
S.protection services & social services not disagg.	1.606.247.903	1.583.380.427	1.339.251.666	84%	84%	80%
Social Protection & Economic Support total (ZAR)	1.919.040.616	1.894.377.838	1.667.513.466	100%	100%	100%






PROGRAMME ENABLERS & SYSTEMS STRENGTHENING ACTIVITIES & FINANCING ENTITY

(2021/22 - 2023/24, ZAR billions)




Pgm.Enablers & S.Strgthning	2021/22	2022/23	2023/24	% 2021/22	% 2022/23	% 2023/24
Strategic planning, co-ordn.	108,417,371	180,069,700	204,233,174	3%	6%	6%
Pgm. Admin & Mgmt	2,768,783,678	2,526,769,700	2,648,865,762	83%	80%	81%
Strategic information	228,547,579	253,159,899	247,487,023	7%	8%	8%
Public systems strgthning	138,581,640	131,339,476	125,694,070	4%	4%	4%
Community system strgthning	59,821,445	76,149,775	44,856,376	2%	2%	1%
Human resources for health	-	-	5,415,241	0%	0%	0%
Pgm.Enablers & S.Strgth not disagg.	15,238,934	-	1,286,090	0%	0%	0%
Pgm.Enablers & S.Strgthning total (ZAR)	3,319,390,648	3,167,488,549	3,277,837,735	100%	100%	100%

SPENDING ON OTHER PROGRAMME AREAS AND FINANCING ENTITY (2021/22 - 2023/24, ZAR billions)



HIV SPENDING BY BENEFICIARIES

(2021/22 - 2023/24, ZAR billions, %)



Beneficiaries of HIV spending (ZAR)	2021/22	2022/23	2023/24	% 2021/22	% 2022/23	% 2023/24
BP.01 People living with HIV	28,910,877,290	29,187,772,350	27,823,220,218	74%	75%	73%
BP.02 Key populations	546,632,131	485,827,457	468,485,363	1%	1%	1%
BP.03 Vulnerable, accessible and other target populations	2,598,054,011	2,386,677,801	2,121,054,340	7%	6%	6%
BP.04 General population	3,058,829,565	3,205,468,420	3,954,950,155	8%	8%	10%
BP.05 Non applicable (ASC which do not have a specific BP)	3,820,626,594	3,624,314,103	3,566,767,783	10%	9%	9%
Total	38,935,019,590	38,890,060,132	37,934,477,858	100%	100%	100%


OVERALL HIV ACTIVITIES – BENEFICIARIES

(2021/22 - 2023/24, ZAR billions, %)

Beneficiaries	2021	2022	2023	% of total exp. (2023/24)	% of sub-category (2023/24)
BP.01 People living with HIV	28,910,877,290	29,187,772,350	27,823,220,218	73%	
Adult and young people living with HIV	1,232,608,186	1,357,699,469	1,564,116,901	4.1%	6%
Children living with HIV	15,860,404	117,866,084	93,527,713	0.2%	0%
People living with HIV not disaggregated	27,662,408,700	27,712,206,798	26,165,575,604	69%	94%
BP.02 Key populations	546,632,131	485,827,457	468,485,363	1%	
Persons who Inject drug users (PWID)	57,814,904	53,023,170	42,891,328	0.1%	9%
Sex workers (SW)	194,450,630	124,693,602	222,460,430	0.6%	47%
Gay men and other men who have sex wi	80,596,676	115,950,917	61,014,454	0.2%	13%
Transgender/Trans	1,894,190	3,684,949	-	0.0%	0%
Inmates of correctional facilities (prisoner	66,585,136	85,404,674	88,788,207	0.2%	19%
Key populations not disaggregated	145,290,594	103,070,144	53,330,944	0.1%	11%
BP.03 Vulnerable, accessible and other tar	2,598,054,011	2,386,677,801	2,121,054,340	6%	
Orphans and vulnerable children (OVC)	635,025,489	578,924,104	521,867,862	1%	25%
New borns with un-determined HIV statu	38,471,246	18,515,657	-	0%	0%
Adolescent girls and young women	613,649,135	368,217,129	417,822,778	1%	20%
People attending STI clinics	-	15,079,399	17,151,996	0%	1%
Employees	2,548,062	852,475	204,170	0.0%	0%
Vulnerable, accessible population not dis	1,308,360,077	1,405,089,037	1,164,007,534	3%	55%
BP.04 General population	3,058,829,565	3,205,468,420	3,954,950,155	10.4%	
General adult population	920,494,745	1,044,154,218	983,621,122	2.6%	25%
Children and Youth	333,971,334	243,879,949	260,013,685	0.7%	7%
General population not disaggregated	1,804,363,486	1,917,434,254	2,711,315,348	7.1%	69%
Non applicable (ASC which do not have a s	3,820,626,594	3,624,314,103	3,566,767,783	9%	
Grand Total	38,935,019,590	38,890,060,132	37,934,477,858		

OVERALL HIV ACTIVITIES – PRODUCTION FACTORS


(2021/22 - 2023/24, ZAR billions, %)



ARVs = average 18% of total HIV spending

Production Factors of HIV spending (ZAR)	2021/22	2022/23	2023/24	% 2021/22	% 2022/23	% 2023/24
Personnel	16,307,440,887	16,220,757,453	16,145,683,332	42%	41%	42%
Operational, overheads, mgmt costs	1,537,987,698	1,681,269,052	1,698,052,888	4%	4%	4%
Medical products & supplies	14,943,625,032	15,369,972,517	14,586,558,552	38%	39%	38%
Contracted services	1,970,373,886	2,334,222,775	2,336,615,746	5%	6%	6%
Training, events, logistics transport, financial	763,760,362	851,922,894	831,666,737	2%	2%	2%
Recurrent expenditure not disagg.	3,508,272,633	2,645,076,280	2,527,193,514	9%	7%	7%
Capital investments	157,388,761	175,709,139	149,417,416	0%	0%	0%
Total HIV (ZAR)	39,188,849,259	39,278,930,110	38,275,188,187	100%	100%	100%

OVERALL HIV ACTIVITIES – FINANCING ENTITIES x PRODUCTION FACTORS (2023/24, %)





FE x Production Factors of HIV (2023/24)	Public Entities	Domestic Private Entities	International Entities	% 2021/22	% 2022/23	% 2023/24
Personnel	11,210,241,234	0	4,935,442,099	39%	0%	60%
Operational, overheads, mgmt costs	1,323,495,797	473,694	374,083,397	5%	0%	5%
Medical products & supplies	13,919,765,418	0	666,793,135	48%	0%	8%
Contracted services	992,763,332	0	1,343,852,415	3%	0%	16%
Training, events, logistics transport, financial support	130,391,748	50,000	701,224,989	0%	0%	9%
Recurrent expenditure not disagg.	1,430,438,693	1,026,902,624	69,852,198	5%	100%	1%
Capital investments	67,548,294	0	81,869,123	0%	0%	1%
Total HIV (ZAR)	29,074,644,515	1,027,426,317	8,173,117,355	100%	100%	100%

Provincial Comparisons



International partners including PEPFAR, GF, UN agencies data were not available per province

PROVINCIAL HIV SPENDING – by programme area (2023/24, ZAR bn)



PROVINCIAL HIV SPENDING by PF & Per Capita (2023/24, ZAR bn)


Provincial HIV spending by production factor (2023/24, %)



Per capita: For each province, we divided the total HIV spending by the total population of that province

PROVINCIAL HIV SPENDING (2023/24, ZAR bn)

SAG HIV spending by PLHIV per province (ZARbn, 2023/24)




This analysis shows how much is spent on HIV per person living with HIV (PLHIV) in each province

Divided the overall public spending by the number of PLHIV per province

■ SAG Total HIV spending
◆ Provincial HIV spending per PLHIV
— National av. HIV spend per capita (all depts)

Divided the public spending on C&T by the number of PLHIV per province


SAG HIV C&T spending by PLHIV per province (ZARbn, 2023/24)



■ SAG HIV C&T spending
◆ Provincial HIV spending per PLHIV
— National av. HIV spend per capita (all depts)


This analysis provides evidence to support more equitable, efficient, and effective allocation of HIV care and treatment resources across provinces, ensuring that funding matches the actual burden of disease and supports progress toward universal access and improved health outcomes

PROVINCIAL HIV SPENDING (2023/24, ZAR bn)



This analysis focuses specifically on ART expenditures relative to the number of people remaining on ART (TROA). It allows for benchmarking ART program costs across provinces, identifying outliers where spending per ART client is unusually high or low. This can inform resource reallocation, highlight potential cost-saving opportunities, and support efforts to standardize care quality and efficiency



PROVINCIAL HIV SPENDING (2023/24, ZAR bn)



TB EXPENDITURE



TB FINANCING ENTITIES

(2021/22- 2023/24, ZARb)



TB PROVIDER OF SERVICES AND ACTIVITIES

(2021/22- 2023/24, ZARb)



TB FINANCING ENTITIES AND ACTIVITIES

(2021/22- 2023/24, ZARb)

TB financing by FE (ZAR)	2021/22	2022/23	2023/24	% 2021/22	% 2022/23	% 2023/24
Public Financing: conditional HIV & TB grant	614.239.496	1.015.834.572	1.238.885.134	19%	30%	37%
Public Financing: voted funds	2.207.907.759	1.954.175.429	1.755.632.522	69%	58%	52%
Private Entitites (medical insurances)	226.840.273	316.854.596	324.446.353	7%	9%	10%
Global Funds	137.769.843	93.743.530	25.615.603	4%	3%	1%
TB Total (ZAR)	3.186.757.371	3.380.608.128	3.344.579.612	100%	100%	100%

Total TB spending per intervention (ZAR)	2021/22	2022/23	2023/24	% 2021/22	% 2022/23	% 2023/24
TB Prevention	157.514.608	114.640.820	170.446.276	5%	3%	5%
TB screening, case detection and diagnosis	2.463.131.666	2.517.189.105	2.478.422.814	77%	74%	74%
TB (drug-sensitive) treatment	493.301.476	663.714.724	625.205.873	15%	20%	19%
TB (drug-resistant) treatment	49.285.434	57.588.882	52.157.235	2%	2%	2%
TB treatment not disaggregated by type of TB	11.503.772	14.880.282	7.457.004	0%	0%	0%
Program management for TB	12.020.414	12.594.314	10.890.410			
TB Total	3.186.757.371	3.380.608.128	3.344.579.612	100%	100%	100%

TB FINANCING ENTITIES AND ACTIVITIES

(2021/22- 2023/24, ZARb)

Total TB spending per intervention by FE	2021	2022	2023	% 2023
FE.01 Public Entities	2.822.147.255	2.970.010.001	2.994.517.656	90%
ASC.03.04 Co-infections and opportunistic infections: prevention and treatment for PLHIV and/or TB	2.810.126.840	2.957.415.687	2.983.627.246	
ASC.03.04.01 TB prevention, case finding, screening, diagnosis, treatment and adl	2.810.126.840	2.957.415.687	2.983.627.246	
ASC.03.04.01.01 TB prevention (including medical prevention, awareness raising	157.514.608	114.640.820	170.446.276	5%
ASC.03.04.01.02 TB screening, case detection and diagnosis (including contact t	2.463.131.666	2.517.189.105	2.478.422.814	74%
ASC.03.04.01.03 TB care and treatment	177.976.794	310.705.480	327.301.152	10%
ASC.03.04.01.98 TB activities not disaggregated	11.503.772	14.880.282	7.457.004	0%
ASC.06.99 Other Programme enablers and systems strengthening n.e.c.	12.020.414	12.594.314	10.890.410	0%
FE.03 International Entities	137.769.843	93.743.530	25.615.603	1%
ASC.03.04 Co-infections and opportunistic infections: prevention and treatment	137.769.843	93.743.530	25.615.603	
ASC.03.04.01 TB prevention, case finding, screening, diagnosis, treatment and adl	137.769.843	93.743.530	25.615.603	
ASC.03.04.01.03 TB care and treatment	137.769.843	93.743.530	25.615.603	1%
FE.02 Domestic Private Entities	226.840.273	316.854.596	324.446.353	10%
ASC.03.04 Co-infections and opportunistic infections: prevention and treatment	226.840.273	316.854.596	324.446.353	
ASC.03.04.01 TB prevention, case finding, screening, diagnosis, treatment and adl	226.840.273	316.854.596	324.446.353	
ASC.03.04.01.03 TB care and treatment	226.840.273	316.854.596	324.446.353	10%
Grand Total	3.186.757.371	3.380.608.128	3.344.579.612	100%

TB SPENDING by Service Provider & Production Factors

(2021/22- 2023/24, ZARb)

TB service providers (ZAR)	2021/22	2022/23	2023/24	% 2021/22	% 2022/23	% 2023/24
Public service providers	2.959.917.098	3.063.754.268	3.020.137.091	93%	91%	90%
For-profit providers	226.840.273	316.854.596	324.446.353	7%	9%	10%
Total TB (ZAR)	3.186.757.371	3.380.608.864	3.344.583.444	100%	100%	100%

TB Production Factors (ZAR)	2021/22	2022/23	2023/24	% 2021/22	% 2022/23	% 2023/24
Personnel	126.982.891	145.048.906	163.275.441	4%	4%	5%
Operational, overheads, mgmt costs	10.472.734	7.203.948	4.700.758	0%	0%	0%
Medical products & supplies	2.792.262.129	2.905.176.501	2.827.765.411	88%	86%	85%
Contracted services	129.984	865.266	1.523.959	0%	0%	0%
Training, events, logistics transport etc.	619.966	1.206.521	823.000	0%	0%	0%
Recurrent expenditure not disagg.	226.840.273	316.854.596	327.806.860	7%	9%	10%
Capital investments	29.449.394	4.252.390	18.684.182	1%	0%	1%
Total TB (ZAR)	3.186.757.371	3.380.608.128	3.344.579.612	100%	100%	100%

THANK YOU

Thanks to:

- ✓ SANAC for leading and co-ordinating the NASA process
- ✓ NASA Reference Group (convened by SANAC)
- ✓ The various funders: GF, USAID, UNAIDS
- ✓ CEGAA team for their execution of this NASA process
- ✓ NDOH and National Treasury
- ✓ GF PRs & PEPFAR
- ✓ All respondents

Queries to:

SANAC:

Ms Billia Luwaca

Billia@sanac.org.za

CEGAA:

Nhlanhla Ndlovu / Silindile Shezi

Nhlanhla@cegaa.org

Silindile@cegaa.org



THE SOUTH AFRICAN NATIONAL AIDS COUNCIL

THE SOUTH AFRICAN AIDS COUNCIL [SANAC] BRINGS TOGETHER GOVERNMENT, CIVIL SOCIETY AND THE PRIVATE SECTOR TO CREATE A COLLECTIVE RESPONSE TO HIV, TB AND STIS IN SOUTH AFRICA. THE COUNCIL IS CHAIRED BY THE DEPUTY PRESIDENT OF SOUTH AFRICA.